AI assistant
Sending…
Actinium Pharmaceuticals, Inc. — Director's Dealing 2018
Mar 8, 2018
34570_dirs_2018-03-08_d9e8bb41-cca8-49ee-bb27-68bb1a77733d.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: Actinium Pharmaceuticals, Inc. (ATNM)
CIK: 0001388320
Period of Report: 2018-03-06
Reporting Person: SETH SANDESH (Director, Chairman & CEO)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2018-03-06 | Common Stock | J | 52500 | $0.50 | Acquired | 128333 | Direct |
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-03-06 | Series A Warrants | $0.60 | J | 13125 | Acquired | 2019-03-06 | Common Stock (13125) | Direct |
| 2018-03-06 | Series B Warrants | $0.70 | J | 39375 | Acquired | 2020-09-06 | Common Stock (39375) | Direct |
More from Actinium Pharmaceuticals, Inc.
Delisting Announcement
2026
May 29
Annual Report
2026
Mar 30
Declaration of Voting Results & Voting Rights Announcements
2026
Mar 26
Board/Management Information
2026
Feb 13
Declaration of Voting Results & Voting Rights Announcements
2025
Nov 26
Interim / Quarterly Report
2025
Nov 14
Annual Report
2025
Nov 5
Proxy Solicitation & Information Statement
2025
Nov 5
Director's Dealing
2025
Aug 20
Interim / Quarterly Report
2025
Aug 8